T1	PROC 46 104	Estudio abierto de extensión y supervisión de la seguridad
T2	DISO 122 138	colitis ulcerosa
#1	AnnotatorNotes T2	C0009324; Ulcerative Colitis; Disease or Syndrome
T3	PROC 164 181	estudios fase III
T4	PROC 220 278	ESTUDIO ABIERTO DE EXTENSIÓN Y SUPERVISIÓN DE LA SEGURIDAD
T5	DISO 296 312	COLITIS ULCEROSA
#2	AnnotatorNotes T5	C0009324; Ulcerative Colitis; Disease or Syndrome
T6	PROC 358 378	ESTUDIOS EN FASE III
T7	DISO 429 463	enfermedad inflamatoria intestinal
#3	AnnotatorNotes T7	C0021390; Inflammatory Bowel Diseases; Disease or Syndrome
T8	DISO 490 506	Colitis Ulcerosa
#4	AnnotatorNotes T8	C0009324; Ulcerative Colitis; Disease or Syndrome
T9	PROC 621 653	estudios controlados en fase III
T10	PROC 706 717	tratamiento
#5	AnnotatorNotes T10	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T11	CHEM 722 733	etrolizumab
#6	AnnotatorNotes T11	C3177463; etrolizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T12	PROC 784 793	protocolo
#7	AnnotatorNotes T12	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T13	CHEM 383 394	ETROLIZUMAB
#8	AnnotatorNotes T13	C3177463; etrolizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T14	PROC 1040 1049	protocolo
#9	AnnotatorNotes T14	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T15	PROC 1085 1096	seguimiento
#10	AnnotatorNotes T15	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T16	CHEM 903 914	etrolizumab
#11	AnnotatorNotes T16	C3177463; etrolizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T17	ANAT 453 463	intestinal
#12	AnnotatorNotes T17	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T18	PROC 878 898	estudios en fase III
T19	CHEM 186 197	etrolizumab
#13	AnnotatorNotes T19	C3177463; etrolizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T20	PROC 1027 1030	OLE
#14	AnnotatorNotes T20	C1709323; Open Label Study; Research Activity (?)
T21	PROC 980 983	OLE
#15	AnnotatorNotes T21	C1709323; Open Label Study; Research Activity (?)
T22	Date 13 17	2013
T23	LIVB 108 117	pacientes
#16	AnnotatorNotes T23	C0030705; Patients; Patient or Disabled Group
T24	LIVB 282 291	PACIENTES
#17	AnnotatorNotes T24	C0030705; Patients; Patient or Disabled Group
T25	LIVB 570 579	pacientes
#18	AnnotatorNotes T25	C0030705; Patients; Patient or Disabled Group
T26	LIVB 837 846	Pacientes
#19	AnnotatorNotes T26	C0030705; Patients; Patient or Disabled Group
T29	LIVB 988 997	Pacientes
#20	AnnotatorNotes T29	C0030705; Patients; Patient or Disabled Group
T30	LIVB 1053 1062	Pacientes
#21	AnnotatorNotes T30	C0030705; Patients; Patient or Disabled Group
T31	Duration 1116 1126	12 semanas
T27	PROC 1293 1320	supervisión de la seguridad
#22	AnnotatorNotes T27	C0150370; Surveillance: safety; Therapeutic or Preventive Procedure
T28	PROC 806 833	supervisión de la seguridad
#23	AnnotatorNotes T28	C0150370; Surveillance: safety; Therapeutic or Preventive Procedure
T32	Neg_cue 921 923	no
T33	Observation 928 933	aptos
#24	AnnotatorNotes T33	C1302261; Patient eligible for clinical trial; Finding
A1	Status T3 History_of
A2	Status T19 History_of
A3	Status T6 History_of
A4	Status T13 History_of
A6	Status T18 History_of
A7	Status T11 History_of
A8	Status T16 History_of
A9	Status T10 History_of
A10	Assertion T33 Negated
#25	AnnotatorNotes T3	C0282461; Phase 3 Clinical Trials; Research Activity
#26	AnnotatorNotes T6	C0282461; Phase 3 Clinical Trials; Research Activity
#28	AnnotatorNotes T18	C0282461; Phase 3 Clinical Trials; Research Activity 
T34	Neg_cue 1324 1326	No
T35	CONC 1331 1353	criterios de exclusión
A11	Assertion T35 Negated
#29	AnnotatorNotes T35	C0680251; Exclusion Criteria; Functional Concept
T36	Observation 1236 1245	condición
#30	AnnotatorNotes T36	C4745084; Medical Condition; Finding
T37	Quantifier_or_Qualifier 1246 1251	nueva
#31	AnnotatorNotes T37	C0205314; New; Qualitative Concept
T38	Neg_cue 1269 1271	no
T39	Quantifier_or_Qualifier 1272 1282	controlada
A12	Assertion T39 Negated
T40	Quantifier_or_Qualifier 1253 1266	significativa
#32	AnnotatorNotes T40	C1546944; Event Seriousness - Significant; Qualitative Concept
T41	Neg_cue 950 952	no
T42	PROC 953 964	inscribirse
A13	Assertion T42 Negated
R1	Negation Arg1:T32 Arg2:T33	
R2	Experiences Arg1:T23 Arg2:T2	
R3	Experiences Arg1:T23 Arg2:T19	
T43	Observation 139 181	previamente inscritos en estudios fase III
R4	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T43	
R5	Experiences Arg1:T24 Arg2:T5	
T44	Observation 333 378	PREVIAMENTE INSCRITOS EN ESTUDIOS EN FASE III
R6	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T44	
R7	Experiences Arg1:T24 Arg2:T13	
T45	Quantifier_or_Qualifier 316 332	MODERADA A GRAVE
#33	AnnotatorNotes T45	C1299393; Moderate to severe; Qualitative Concept
R8	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T45	
R9	Location_of Arg1:T17 Arg2:T7
R10	Used_for Arg1:T11 Arg2:T10	
R11	Experiences Arg1:T25 Arg2:T10	
T46	Observation 592 653	inscritos previamente en los estudios controlados en fase III
A5	Status T9 History_of
R12	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T46	
T47	Observation 660 697	satisfacen los criterios de idoneidad
#27	AnnotatorNotes T47	C1302261; Patient eligible for clinical trial; Finding (?)
T48	Observation 851 898	participaron en uno de los estudios en fase III
R15	Experiences Arg1:T26 Arg2:T16	
R16	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T33	
#34	AnnotatorNotes T42	C4041024; Enrollment in clinical trial; Research Activity
R17	Negation Arg1:T41 Arg2:T42	
T49	Observation 1002 1031	provienen de la parte 1 (OLE)
T50	Observation 1071 1112	completado el seguimiento de la seguridad
R19	Has_Duration_or_Interval Arg1:T15 Arg2:T31	
T51	Observation 1136 1146	participar
#35	AnnotatorNotes T51	C1278516; Patient participation status; Finding
R21	Before Arg1:T50 Arg2:T51	
R23	Before Arg1:T15 Arg2:T51	
R24	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T37	
R25	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T40	
R26	Negation Arg1:T38 Arg2:T39	
R27	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T39	
R28	Negation Arg1:T34 Arg2:T35	
#36	AnnotatorNotes T50	C5554829; Follow-Up Completed; Finding (?)
#37	AnnotatorNotes T9	C0282461; Phase 3 Clinical Trials; Research Activity + C0681867; Controlled Study; Research Activity
A14	Experiencer T30 Patient
A15	Experiencer T29 Patient
A16	Experiencer T23 Patient
A17	Experiencer T24 Patient
A18	Experiencer T25 Patient
A19	Experiencer T26 Patient
